2026 ASCO Highlights Webinar-Recording

Video Transcription

Video Summary

The webinar, “Highlights of ASCO 2026,” reviewed major lung cancer advances across targeted therapy and immunotherapy.<br /><br />Dr. Angel Chin highlighted three targeted-therapy studies. In LIBRETTO-432, adjuvant selpercatinib for resected RET-positive stage II–IIIA NSCLC dramatically improved event-free survival versus placebo, with only 4 events on selpercatinib versus 19 on placebo. In the 7-year CROWN update, lorlatinib continued to show durable first-line benefit in ALK-positive metastatic NSCLC, with median PFS still not reached and strong intracranial control. The phase 2 LOREN study suggested neoadjuvant lorlatinib has promising pathologic response rates in stage III ALK-positive disease, but key questions remain about optimal duration, the role of chemotherapy, and the best endpoints.<br /><br />Dr. Samuel Rosner discussed uncommon EGFR and small cell lung cancer. CRYSTAL-2 showed encouraging outcomes for first-line amivantamab plus lazertinib in atypical EGFR mutations, including compound alterations. WUKONG-20H found that sunvozertinib improved PFS over chemotherapy in EGFR exon 20 insertion NSCLC, though access and CNS activity remain concerns. In the DELPHI-304 post-hoc analysis, tarlatamab demonstrated notable intracranial activity in relapsed small cell lung cancer, with low rates of neurologic immune-related toxicity, though real-world management issues such as dysgeusia were discussed.<br /><br />Dr. Rebecca Heist presented three studies in EGFR-negative/driver-negative NSCLC. OPTI-1 showed sacituzumab govitecan plus pembrolizumab improved PFS over pembrolizumab alone in first-line PD-L1-positive disease. TRITON suggested tremelimumab/durvalumab plus chemotherapy may benefit STK11/KEAP1/KRAS-mutant nonsquamous NSCLC. HARMONY-6 showed the VEGF/PD-1 bispecific ivonescimab plus chemotherapy improved survival in squamous NSCLC, with ongoing questions about safety in central tumors and older patients.<br /><br />The session ended with discussion on adjuvant chemotherapy, treatment duration, MRD testing, toxicity management, and how to select patients for these new regimens.

Meta Tag

Concept Advanced Lung Cancer

Concept Targeted Therapy

Concept Anaplastic Lymphoma Kinase

Concept RET

Concept Event-Free Survival

Keywords

ASCO 2026

lung cancer

targeted therapy

immunotherapy

selpercatinib

lorlatinib

amivantamab

lazertinib

tarlatamab

ivonescimab

Advanced Lung Cancer

Targeted Therapy

Anaplastic Lymphoma Kinase

RET

Event-Free Survival